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behavior: diabetics and those with hypertension. METHODS:
Analyses are based on a nationally representative sample from
the Medicare Current Beneﬁciary Survey (MCBS) for the years
2000–2005. MCBS is a longitudinal survey and provide detailed
information on prescription drug coverage, exercise, weight, diet,
alcohol consumption, and smoking behavior. The analysis is
restricted to non-institutionalized persons above 64 years of age
with at least 2 years of data. We pay particular attention to the
non-random nature of prescription drug coverage and the selec-
tion bias caused by it. Speciﬁcally, estimates are obtained using
longitudinal data and multivariable regression models that
control for observed characteristics and unmeasured person-
speciﬁc effects (i.e., ﬁxed effects). RESULTS: An average of 16%
of the elderly switched coverage in any two consecutive years,
providing sufﬁcient variation in prescription drug coverage to
conduct ﬁxed effects analysis. In general, we ﬁnd limited evidence
of prescription drug coverage affecting health behaviors. The
lone exception was for those in public programs, where one
speciﬁcation reﬂected that elderly in the public programs were 13
percentage points (30%) less likely to participate in physical
activity than those with no prescription drug coverage after
controlling for health status. CONCLUSIONS: Although, we did
not ﬁnd any evidence of ex ante moral hazard with employer-
sponsored and HMO coverage, those in public program altered
their behavior signiﬁcantly upon gaining prescription drug
coverage.
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OBJECTIVES: The experience of TIA patients in the UK NHS
can be quite disparate. Patients presenting to primary care are
often referred to a weekly clinic, creating a delay in access to
effective treatments for this condition. The recent EXPRESS
study by Rothwell et al. (Rothwell, Peter M., et al. Lancet.
Online 9 Oct 2007 DOI:10.1016/S0140-6736(07)61448-2)
clearly demonstrated that a greater focus on effectively managing
TIA could have a signiﬁcant impact on subsequent stroke rates.
We wanted to examine how the implementation of the care
pathway outlined in Phase 2 of the EXPRESS study could affect
rates of stroke, and to explore the ﬁnancial implications of such
a shift in care. METHODS: We developed an economic model to
estimate the costs and savings associated with setting up a rapid
assessment and treatment clinic for patients with suspected TIA,
in line with Phase 2 of the EXPRESS study. We used a local
population of 500,000 people with an assumed annual incidence
of TIA of 0.19%. Current management was based on national
clinical guidelines and common clinical practice. We included all
direct costs associated with care (medications, diagnostics and
staff), and modeled the impact of changing management over a
three-year time horizon, in line with NHS planning timeframes.
RESULTS: For an assumed population of 500,000, changing the
pathway of care for TIA management resulted in 295 future
stroke events avoided over three years. As a result, the additional
costs associated with changing the pathway of care for TIA were
greatly outweighed by the savings generated through avoiding
acute management costs associated with stroke. CONCLU-
SIONS: The model suggests that the implementation of the
changes outlined in phase 2 of the EXPRESS study is cost saving
for a local population of 500,000 with an assumed TIA rate of
0.19%.
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OBJECTIVES: The aim of this study was to collect comparable
and reliable data on the lipid lowering therapy in Slovakia during
the period 1996–2006. The special interest was paid to the trend
of the statin and ﬁbrate usages. METHODS: Data of wholesalers
(following ATC/DDD), who are legally obliged to provide this
information to the Slovak Institute for Drug Control, was used
for the analysis. The results were expressed in the numbers of the
packages, ﬁnance units (€) and deﬁned daily doses per 1000
inhabitants per day (DID). RESULTS: The collected data showed
large increases in hypolipidemic consumption from 1996 to 2006
in term of DID (in 1996 (4.18), in 2001 (16.64), in 2006 (48.80).
A signiﬁcant increase in statin consumption (in 1996 (1.97), in
2001 (9.76) and in 2006 (39.66) and slight increase in ﬁbrate
consumption (in 1996 (3.59), in 2001 (6.76) and in 2006 (7.84)
in term of DID can be seen from this analysis. From the reim-
bursement point of view, simvastatin (in 2000 was reimbursed at
the level of €0.84 per DDD, in 2006 the reimbursement level was
at €0.14), ﬂuvastatin (in 2000 was reimbursed at the level of
€0.75 per DDD, in 2006 the reimbursement level was at €0.46),
atorvastatin (in 2000 was reimbursed at the level of €0.89 per
DDD, in 2006 the reimbursement level was at €0.22). Financial
expenditures were for statins (in 1996 (€989,000), in 2001
(€17,636,000) and in 2006 (€15,458,000) and for ﬁbrates
(in 1996 (€2,743,000), in 2001 (€5,570,000) and in 2006
(€3,517,000). CONCLUSIONS: Usage of generic drugs for the
treatment of hypercholesterolemia brought about a dramatic
increase in hypolipidemic consumption and the ﬁnancial expen-
ditures for health insurance funds have remained under control.
PCV112
STATINS USE IN PATIENTS WITH A RECENT ISCHEMIC
STROKE: RESULTS FROMTHE STROKE ANALYZER DATABASE
Nasuti PI, Belilty J, Hamad B
IMS Health, London, UK
OBJECTIVES:Assess the usage of statins in hospital after an acute
ischemic event and identify differences across Europe.
METHODS: Consecutive patients diagnosed for Ischemic Stroke
were analyzed in 2006 and 2007 in Germany, France, Italy, Spain
and UK using the Stroke Analyzer database. This was a retrospec-
tive study. RESULTS: A total of 4930 Ischemic Stroke cases were
enrolled from July 2006 until July 2007. Data were reported from
around 300 stroke specialists, neurologists, general medicine spe-
cialists. The most common treatments administered in hospital
were: aspirin 73%, statins 55%, LMWH 48%, ACE inhibitors
46%, beta blockers 21%, clopidogrel 18%. The majority of the
2726 patients treated with statins in hospital received simvastatin
47%, atorvastatin 40% and pravastatin 8%. The most common
simvastatin ﬁrst doses used were: 40 mg (48%) and 20 mg (42%).
The atorvastatin starting doses administered were mainly 20 mg
(34%), 40 mg (27%) and 80 mg (16%) atorvastatin (Spain were
leading with 25% of atorvastatin patients receiving a start dose of
80 mg). A total of 1023 patients (21%) were already receiving a
long term treatment with a statin prior to hospital admission.
Despite the fact that 56% of all ischemic stroke patients did not
have dyslipidemia, 11%of themwere already on statins before the
stroke event. Almost 31% of patients already had a previous
stroke or TIA event and 13% had a myocardial infarction more
than 1 month before the current ischemic stroke event. Treatment
with a statinwas initiated on the same day of admission to hospital
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